CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.
CubicPV is a solar industry that relies on legacy technologies with inherent limitations. Conventional solar modules convert sunlight to electricity using a single light-absorbing material and are nearing an efficiency threshold.
Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches.
Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required.
Akili is based in Boston, Massachusetts.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Cohere Health, Inc., founded in 2019 and headquartered in Boston, Massachusetts, develops a software platform aimed at enhancing collaboration among healthcare stakeholders. The company focuses on improving the patient journey by creating a user-friendly experience for patients, healthcare providers, and health plans. Its mission includes increasing the quality of care, reducing overall healthcare costs, and fostering transparency throughout the patient care process. By leveraging technology, Cohere Health seeks to address the complexities of healthcare delivery, ultimately benefiting all parties involved.
Tausight, Inc. develops a software for reducing healthcare cyber incidents of patient data theft. It serves chief information officer of health care sector. Tausight was founded in 2018 and is based in Sudbury, Massachusetts with additional office in San Francisco, California.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Pandion Operations, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases. Its lead product candidate, PT101, is an engineered variant of interleukin-2 (IL-2) currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions. Other product candidates include PT627, a systemic PD-1 agonist in preclinical studies; PT001, a bifunctional molecule designed to achieve tissue-selective immunomodulation in the gastrointestinal tract; and PT002, which combines an IL-2 mutein with a tether module for similar localized effects. The company collaborates with Astellas Pharma Inc. to develop immunomodulators aimed at autoimmune diseases specifically affecting the pancreas. Headquartered in Watertown, Massachusetts, Pandion Operations seeks to create innovative therapies that can provide durable and tissue-specific treatment options for patients suffering from these conditions.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Mesodyne's solution is a novel ultra-high energy density, multi-fuel, silent, compact power generator. Our generators convert fuel to electricity with heat and light as intermediaries: a small micro combustor heats a photonic crystal to incandescence and the resulting light is tailored to the bandgap of an infrared cell resulting in unprecedented high efficiencies.
Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses.
The company was founded in 2019 and headquartered in Waltham, Massachusetts.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Private Equity Round in 2019
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
Drizly is an e-commerce alcohol marketplace and the best way to shop beer, wine, and spirits. With the speed and convenience of on-demand delivery and shipping, Drizly partners with retailers in 235 markets to offer consumers of legal drinking age unrivaled selection and a transparent, personalized shopping experience. Backed by world-class institutional investors, Drizly partners with retailers to bring their shelves online, helping them to reach new customers, tap into key market and customer insights, and diversify their business to grow sales.
ClearSky Data’s global storage network simplifies the entire data lifecycle and delivers enterprise storage as a fully managed service. Its storage is designed for business agility. ClearSky simplifies enterprise storage by providing an SLA-based managed service across the global network. The company's patent-pending Smart Tiered Caching continually categorizes data and places it in the right cache layer (hot, warm, cold) based on evolving usage requirements and customer policies. Customers simply scale as needed, using the ClearSky dashboard to add unlimited capacity with a few clicks. All data can be moved across the ClearSky network to meet a variety of use cases including data center migration, load balancing, expansion into new regions, or disaster recovery. ClearSky has partnered with major public clouds to place hot and warm cache copies at the cloud edge. The result: customers get low-latency access to cloud instances, providing a new cost-effective option to run their most demanding workloads. The total cost of ownership (TCO) of storing data using the ClearSky service is about 1/3 the cost of managing it in a company’s data center on physical storage arrays. By leveraging the architecture and building redundancy into all cache layers and network paths, ClearSky is able to provide an enterprise-class service with guaranteed high availability. Industry-leading security technologies and best practices ensure that customer data is always protected and isolated from the moment it enters the ClearSky network. Customers simply plug into the ClearSky service to get the storage they need, when and where they need it, with the security, scalability, and resilience that a business depends on.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Pandion Operations, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases. Its lead product candidate, PT101, is an engineered variant of interleukin-2 (IL-2) currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions. Other product candidates include PT627, a systemic PD-1 agonist in preclinical studies; PT001, a bifunctional molecule designed to achieve tissue-selective immunomodulation in the gastrointestinal tract; and PT002, which combines an IL-2 mutein with a tether module for similar localized effects. The company collaborates with Astellas Pharma Inc. to develop immunomodulators aimed at autoimmune diseases specifically affecting the pancreas. Headquartered in Watertown, Massachusetts, Pandion Operations seeks to create innovative therapies that can provide durable and tissue-specific treatment options for patients suffering from these conditions.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Suono Bio is developing platform technology designed to enable ultra-rapid delivery of therapeutics, including proteins and nucleic acids, to the gastrointestinal (GI) tract. Preclinical studies have demonstrated the capacity to deliver small molecules, proteins, vaccines, and nucleic acids locally and systemically, validating further development of the system.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.
Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
Drizly is an e-commerce alcohol marketplace and the best way to shop beer, wine, and spirits. With the speed and convenience of on-demand delivery and shipping, Drizly partners with retailers in 235 markets to offer consumers of legal drinking age unrivaled selection and a transparent, personalized shopping experience. Backed by world-class institutional investors, Drizly partners with retailers to bring their shelves online, helping them to reach new customers, tap into key market and customer insights, and diversify their business to grow sales.
Incredible Foods, Inc. manufactures and sells non-dairy frozen products under the brand name perfectlyfree. Its products include fruit bites, frozen bites, and frozen pints. It serves customers through a network of stores. Incredible Foods, Inc. was formerly known as Wikifoods, Inc. and changed its name to Incredible Foods, Inc. in July 2016. The company was founded in 2012 and is based in Boston, Massachusetts. Incredible Foods, Inc. operates as a subsidiary of Quantum Designs, LLC.
Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Founded in 2014 to advance technology developed at Tufts University and the University of Pittsburgh, Sofregen is a pioneer in the use of silk, nature’s healing fiber, in a variety of forms to help physicians address soft tissue defects, giving patients a fresh start, restoring confidence, and improving quality of life. Sofregen is committed to restoring function and cosmetic appearance for medical and aesthetic patients worldwide.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases.
It was founded in 2009 and headquartered in Cambridge, Massachusetts.
ClearSky Data’s global storage network simplifies the entire data lifecycle and delivers enterprise storage as a fully managed service. Its storage is designed for business agility. ClearSky simplifies enterprise storage by providing an SLA-based managed service across the global network. The company's patent-pending Smart Tiered Caching continually categorizes data and places it in the right cache layer (hot, warm, cold) based on evolving usage requirements and customer policies. Customers simply scale as needed, using the ClearSky dashboard to add unlimited capacity with a few clicks. All data can be moved across the ClearSky network to meet a variety of use cases including data center migration, load balancing, expansion into new regions, or disaster recovery. ClearSky has partnered with major public clouds to place hot and warm cache copies at the cloud edge. The result: customers get low-latency access to cloud instances, providing a new cost-effective option to run their most demanding workloads. The total cost of ownership (TCO) of storing data using the ClearSky service is about 1/3 the cost of managing it in a company’s data center on physical storage arrays. By leveraging the architecture and building redundancy into all cache layers and network paths, ClearSky is able to provide an enterprise-class service with guaranteed high availability. Industry-leading security technologies and best practices ensure that customer data is always protected and isolated from the moment it enters the ClearSky network. Customers simply plug into the ClearSky service to get the storage they need, when and where they need it, with the security, scalability, and resilience that a business depends on.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Arsenal Medical, Inc., a platform technology company, develops polymer based foams and fibers for the treatment of vascular diseases. It develops in-situ forming foams to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair. The company also provides AxioCore, a core-sheath nanofiber and microfiber technology constructed from known biomaterials, which is used for cell integration and tissue regeneration enabling controlled delivery of a range of biologics and therapeutics. Arsenal Medical, Inc. was founded in 2005 and is based in Watertown, Massachusetts.
Drizly is an e-commerce alcohol marketplace and the best way to shop beer, wine, and spirits. With the speed and convenience of on-demand delivery and shipping, Drizly partners with retailers in 235 markets to offer consumers of legal drinking age unrivaled selection and a transparent, personalized shopping experience. Backed by world-class institutional investors, Drizly partners with retailers to bring their shelves online, helping them to reach new customers, tap into key market and customer insights, and diversify their business to grow sales.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Arsia Therapeutics’ mission is to improve access to these life-saving drugs, make them more patient-friendly, and reduce healthcare costs by enabling subcutaneous delivery in non-hospital settings. Biopharmaceuticals are much larger and more fragile than traditional small-molecule drugs. Due to their size, large doses of biologics are often required; and because of their fragility, these drugs must be administered by injection instead of orally. Biologics become unstable and extremely viscous at the high concentrations required for traditional low-volume injections. Consequently, they are frequently administered as high-volume, slow intravenous infusions in a hospital setting. From a patient perspective, receiving treatment via subcutaneous administration can be preferable to intravenous infusion. Subcutaneous administration removes the need for invasive IV ports. Administration at home eliminates time-intensive and expensive hospital visits. Achieving high doses of biologics in a volume suitable for subcutaneous administration presents significant formulation challenges. The major limiting factor is viscosity, which arises when biomolecules are formulated at high concentration. Arsia’s mission is to produce high-concentration biopharmaceutical products with low viscosity, suitable for small-volume subcutaneous injection. Our proprietary platform technology reduces the viscosity of biologics through the addition of inactive ingredients (excipients). Because Arsia’s technology works at the formulation stage, the molecular structure of the drug itself is not affected. Arsia’s technology provides i) a formulation solution for new products in development that have viscosity challenges, ii) a life-cycle management strategy for existing products and iii) a way to differentiate those products from others on the market. For more information on partnering with Arsia, please contact us.
WellAir delivers energy-efficient technologies that enable safe indoor spaces for the health and wellbeing of all individuals.
WellAir’s mission is to mitigate microorganisms that lead to infectious diseases, including viruses, by delivering innovative and powerful air cleaning technology and surface disinfection devices.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
Private Equity Round in 2014
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.